Exagen Inc. (XGN) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Exagen Inc. is a medical technology company focused on the AVISE® brand of diagnostic testing products for rheumatic and autoimmune diseases. This report covers the quarterly period ended March 31, 2025. The company operates a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $15,498 | $14,415 |
| Gross Margin | $9,123 (58.9%) | $8,598 (59.6%) |
| Operating Loss | $(3,365) | $(3,003) |
| Net Loss | $(3,752) | $(3,360) |
| Net Loss Per Share (Basic/Diluted) | $(0.20) | $(0.19) |
| Cash and Cash Equivalents (End of Period) | $11,194 | $22,036 |
| Total Debt (Current + Non-Current) | $20,940 | $20,245 |
| Net Cash Used in Operating Activities | $(10,671) | $(9,040) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 7.5% year-over-year, driven primarily by Average Selling Price (ASP) expansion from new biomarkers and a 2% increase in test volume for the flagship AVISE® CTD test.
- Margin Compression: Gross margin percentage decreased slightly to 58.9% from 59.6%, attributed to bearing costs for new biomarkers under client direct bill contracts prior to price amendments.
- Expense Increases: Operating expenses rose 7.6% due to increased headcount (employee-related expenses) and travel/entertainment costs. SG&A increased by $0.7 million, and R&D increased by $0.2 million.
- Liquidity Decline: Cash and cash equivalents decreased by approximately $10.8 million during the quarter. This was driven by a net loss of $3.8 million and a significant increase in accounts receivable ($6.9 million) due to strategic delays in claim submissions as part of revenue cycle management initiatives.
Outlook, Risks, and Subsequent Events
- Subsequent Financing: On April 25, 2025, Exagen entered into a $75.0 million Perceptive Term Loan Facility. An initial tranche of $25.0 million was funded, with $19.7 million used to repay the 2017 Term Loan. The facility includes revenue-based milestones for additional tranches and requires a minimum unrestricted cash balance of $3.0 million.
- Product Pipeline: The company plans to commercially launch PAD4 biomarkers by the end of 2025 and expects results for Lupus Nephritis biomarkers in Q3 2025. New SLE and RA biomarkers were launched in January 2025.
- Regulatory Risks: A federal court ruled in March 2025 that the FDA lacks statutory authority to regulate Laboratory Developed Tests (LDTs), though the FDA may appeal. Additionally, new U.S. tariffs on imports announced in April 2025 pose a risk to supply chain costs for reagents sourced internationally.
- Litigation: A qui tam complaint was dismissed with prejudice in March 2025, but the relator filed an appeal on April 14, 2025. The company intends to vigorously defend against the appeal.
Investor Verification Checklist
- Cash Runway: Verify the impact of the new $25M Perceptive loan on the company's liquidity runway, given the $10.8M cash burn in Q1.
- Debt Covenants: Confirm compliance with the new Perceptive facility covenants, specifically the $3.0 million minimum cash balance and quarterly revenue targets starting Q2 2025.
- Receivables Collection: Monitor the reversal of the accounts receivable buildup in Q2-Q4 2025 to ensure cash flow improves as expected from the delayed claim submissions.
- ASP Realization: Track whether the new biomarkers successfully drive sustained ASP growth and offset the initial margin compression observed in Q1.
- Supply Chain Costs: Assess the potential impact of new U.S. tariffs on the cost of imported reagents and the ability to pass these costs to payors.